{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:10:15Z","timestamp":1784945415225,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.lanepe.2022.100324","type":"journal-article","created":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T12:21:13Z","timestamp":1644063673000},"page":"100324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis"],"prefix":"10.1016","volume":"15","author":[{"given":"Cindy","family":"Neuzillet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Teissier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-2680","authenticated-orcid":false,"given":"St\u00e9phane","family":"Bou\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Li\u00e8vre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2022.100324_bib0001","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.lanepe.2022.100324_bib0002","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.ejca.2015.07.034","article-title":"Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: results of EUROCARE-5","volume":"51","author":"Lepage","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lanepe.2022.100324_bib0003","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.lanepe.2022.100324_bib0004","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","author":"Bridgewater","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanepe.2022.100324_bib0005","first-page":"e3962","article-title":"Incidence of cholangiocarcinoma in the USA from 2001 to 2015: a US cancer statistics analysis of 50 states","volume":"11","author":"Patel","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.lanepe.2022.100324_bib0006","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lanepe.2022.100324_bib0007","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanepe.2022.100324_bib0008","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.lanepe.2022.100324_bib0009","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanepe.2022.100324_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.33146","article-title":"Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer","author":"Neuzillet","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.lanepe.2022.100324_bib0011","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.lanepe.2022.100324_bib0012","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.lanepe.2022.100324_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2020.05.009","article-title":"Continuum of care for advanced biliary tract cancers","author":"Vienot","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.lanepe.2022.100324_bib0014","unstructured":"http:\/\/www.atih.sante.fr."},{"key":"10.1016\/j.lanepe.2022.100324_bib0015","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jhep.2010.06.039","article-title":"Trends in the incidence and management of biliary tract cancer: a French population-based study","volume":"54","author":"Lepage","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanepe.2022.100324_bib0016","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/MEG.0000000000001337","article-title":"Epidemiology of intrahepatic, perihilar, and distal cholangiocarcinoma in the French population","volume":"31","author":"Al Mahjoub","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.lanepe.2022.100324_bib0017","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu3181994"},{"key":"10.1016\/j.lanepe.2022.100324_bib0018","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pemazyre#authorisation-details-section"},{"key":"10.1016\/j.lanepe.2022.100324_bib0019","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.lanepe.2022.100324_bib0020","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.lanepe.2022.100324_bib0021","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis","volume":"72","author":"Clements","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanepe.2022.100324_bib0022","unstructured":"https:\/\/www.snfge.org\/content\/8-cancer-des-voies-biliaires"},{"issue":"11","key":"10.1016\/j.lanepe.2022.100324_bib0023","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.3390\/cancers12113182","article-title":"Non-alcoholic steatohepatitis as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role","volume":"12","author":"De Lorenzo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lanepe.2022.100324_bib0024","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776222000175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776222000175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T04:48:11Z","timestamp":1763009291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776222000175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":24,"alternative-id":["S2666776222000175"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2022.100324","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2022.100324","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100324"}}